AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance
Fuels Ambition To Be Leading Heart Failure Firm
The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.
You may also be interested in...
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.
Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.
AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications.